Safety and Efficacy of Double Antithrombotic Therapy of Oral Anticoagulants in Patients With Atrial Fibrillation Coronary Intervention: A Systematic Review and Metaé

Journal of the American Heart Association 9, e017212

DOI: 10.1161/jaha.120.017212

Citation Report

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Safety and Efficacy of Double Antithrombotic Therapy With Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e017212.   | 1.6 | 52        |
| 2  | Safety and efficacy of P2Y <sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opinion on Drug Safety, 2021, 20, 9-21.   | 1.0 | 18        |
| 3  | Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice. European Journal of Clinical Pharmacology, 2021, 77, 709-716.   | 0.8 | 7         |
| 4  | Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f50-f60. | 1.4 | 24        |
| 5  | Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.   | 1.6 | 119       |
| 6  | Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men. Expert Review of Cardiovascular Therapy, 2021, 19, 301-312.  | 0.6 | 9         |
| 7  | Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation. American Journal of Cardiology, 2021, 144, S32-S39.  | 0.7 | 2         |
| 8  | Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. Cardiovascular Revascularization Medicine, 2022, 36, 99-106.  | 0.3 | 3         |
| 9  | Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation. US Cardiology Review, $0,15,.$   | 0.5 | 0         |
| 10 | Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials. Current Opinion in Cardiology, 2021, 36, 390-396.  | 0.8 | 5         |
| 11 | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update. Frontiers in Cardiovascular Medicine, 2021, 8, 660986.  | 1.1 | 3         |
| 12 | Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral<br>Anticoagulation. Deutsches Ärzteblatt International, 2021, 118, .  | 0.6 | 2         |
| 13 | An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?. Expert Opinion on Pharmacotherapy, 2021, 22, 2033-2051.  | 0.9 | 3         |
| 14 | Bleeding avoidance strategies in percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 117-132.  | 6.1 | 71        |
| 15 | Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation, 2021, 144, 1196-1211.  | 1.6 | 41        |
| 16 | Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. American Heart Journal, 2021, 242, 71-81.  | 1.2 | O         |
| 17 | One-year clinical outcome of patients with left ventricular thrombus after acute myocardial infarction discharged on triple or dual antithrombotic therapy. Journal of Thrombosis and Thrombolysis, 2022, 53, 410-416.  | 1.0 | 3         |
| 18 | Correspondence. Deutsches Ärzteblatt International, 2021, 118, 739-740.   | 0.6 | О         |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Network Meta-analysis and Trial Sequential Analysis for Atrial Fibrillation Patients Receiving PCI or with ACS. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, .  | 0.6 | 0         |
| 20 | Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes<br>Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 512.   | 1.0 | 3         |
| 21 | Diagnosis and Treatment of Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2022, 327, 662.   | 3.8 | 219       |
| 22 | The optimal duration of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. International Journal of Cardiology, 2022, 357, 33-38. | 0.8 | 5         |
| 23 | Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention, 2022, 17, e1371-e1396.  | 1.4 | 94        |
| 24 | The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Progress in Cardiovascular Diseases, 2021, 69, 11-17.  | 1.6 | 1         |
| 25 | Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. Expert Review of Cardiovascular Therapy, 2021, 19, 1097-1117.   | 0.6 | 4         |
| 26 | New oral anticoagulants in nonvalvular atrial fibrillation. , 2022, 1, 22-27.  |     | 0         |
| 27 | In the search of the  sweet spot' for aspirin discontinuation time in AF patients post PCI. International Journal of Cardiology, 2022, , .   | 0.8 | 0         |
| 28 | Things We Do for No Reasonâ,,¢: Routine use of triple anticoagulant therapy in patients with both nonvalvular atrial fibrillation and percutaneous coronary intervention. Journal of Hospital Medicine, 2022, 17, 917-920.   | 0.7 | 0         |
| 29 | Dual versus triple antithrombotic therapy for atrial fibrillation-ACS/PCI: One size does not fit all. Cardiovascular Revascularization Medicine, 2022, , .   | 0.3 | 0         |
| 30 | P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.   | 6.1 | 30        |
| 31 | The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy, 0, , .   | 1.3 | 0         |
| 32 | Antithrombotic therapy after transcatheter aortic valve implantation. Expert Review of Medical Devices, 2022, 19, 499-513.   | 1.4 | 2         |
| 33 | Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. Pharmacogenomics, 2022, 23, 723-737.   | 0.6 | 21        |
| 34 | Recent Advances in Antiplatelet Therapy in Complex Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2022, 11, 419-428.   | 0.2 | 0         |
| 35 | The Impact of Antithrombotic Therapy in Patients with De-compensated Heart Failure and Iron. Balneo and PRM Research Journal, 2022, 13, 512.   | 0.1 | 1         |
| 36 | Therapeutic uncertainties: first finding of atrial fibrillation in acute coronary syndrome. European<br>Heart Journal Supplements, 2022, 24, 143-146.  | 0.0 | 4         |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2023, 55, 42-50.  | 1.0 | 2         |
| 38 | Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Expert Opinion on Pharmacotherapy, 2023, 24, 453-471. | 0.9 | 5         |
| 39 | Antithrombotic Management in AF Patients Following Percutaneous Coronary Intervention: A European Perspective. Interventional Cardiology Review, 0, $18$ , .   | 0.7 | 3         |
| 40 | Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review. Journal of Cardiovascular Development and Disease, 2023, 10, 135.                                      | 0.8 | 3         |
| 41 | A network meta-analysis of the antithrombotic strategies in patients with atrial fibrillation and percutaneous coronary interventions: Focus on bleeding. Hellenic Journal of Cardiology, 2023, 73, 69-72.     | 0.4 | 1         |